PURPOSE: The aim of this prospective 12-month follow-up study is to evaluate the persistence of the treatment effect achieved during the initial course of peroneal electrical Transcutaneous NeuroModulation (peroneal eTNM®) in patients with overactive bladder (OAB). METHODS: This study enrolled 21 female patients who participated in two previous clinical studies designed to assess the efficacy and safety of peroneal eTNM®. The patients were left without subsequent OAB treatment and were invited to attend regular follow-up visits every 3 months. The patient's request for additional treatment was considered an indicator of the withdrawal of the treatment effect of the initial course of peroneal eTNM®. The primary objective was the proportion of patients with persisting treatment effect at follow-up visit 12 months after initial course of peroneal eTNM®. Descriptive statistics are presented using median, correlation analyses were computed using a nonparametric Spearman correlation. RESULTS: The proportion of patients with persistent therapeutic effect of the initial course of peroneal eTNM® was 76%, 76%, 62% and 48% at 3, 6, 9 and 12 months, respectively. There was a significant correlation between patient reported outcomes and the number of severe urgency episodes with or without urgency incontinence as reported by patients at each follow-up visit (p = 0.0017). CONCLUSION: The treatment effect achieved during the initial phase of peroneal eTNM® persists for at least 12 months in 48% of patients. It is likely that the duration of effects is dependent on the length of the initial therapy.

Biomedical Laboratory and Research Unit of Urology Department of Clinical Research University of Southern Denmark Odense Denmark

Department of Surgical Studies Faculty of Medicine Ostrava University Ostrava Czech Republic

Department of Urology 2nd Faculty of Medicine of Charles University and Motol University Hospital Prague Czech Republic

Department of Urology Erasmus Medical Center Rotterdam The Netherlands

Department of Urology Odense University Hospital Odense Denmark

Department of Urology University Hospital Ostrava Czech Republic

Gynuro s r o Ostrava Czech Republic

Urological Office Poliklinika RAVAK Příbram Czech Republic

Zobrazit více v PubMed

Huang J, Fan Y, Zhao K et al (2002) Comparative efficacy of neuromodulation technologies for overactive bladder in adults: a network meta-analysis of randomized controlled trials. Neuromodulation S1094–7159(22):00752–00758

Sirls ER, Killinger KA, Boura JA, Peters KM (2018) Percutaneous tibial nerve stimulation in the office setting: real-world experience of over 100 patients. Urology 113:34–39 PubMed DOI

Du C, Berg W, Siegal AR et al (2021) Real-world compliance with percutaneous tibial nerve stimulation maintenance therapy in an American population. Urology 153:119–123 PubMed DOI

Del Río-Gonzalez S, Aragon IM, Castillo E et al (2017) Percutaneous tibial nerve stimulation therapy for overactive bladder syndrome: clinical effectiveness, urodynamic, and durability evaluation. Urology 108:52–58 PubMed DOI

Krhut J, Rejchrt M, Slovak M, Dvorak RV, Peter L, Blok BFM, Zvara P (2023) Prospective, randomized, multicenter trial of peroneal electrical transcutaneous neuromodulation versus solifenacin in treatment of naïve patients with overactive bladder. J Urol 209(4):734–741 PubMed DOI

Krhut J, Rejchrt M, Slovak M, Dvorak RV, Grepl M, Zvara P (2022) Peroneal electrical transcutaneous neuromodulation in the home treatment of the refractory overactive bladder. Int Urogynecol J. https://doi.org/10.1007/s00192-022-05359-3 PubMed DOI

Krhut J, Peter L, Rejchrt M, Slovak M, Skugarevska B, Zvara P (2021) Peroneal electric transcutaneous neuromodulation (eTNM®): a novel method for the treatment of the overactive bladder. J Healthc Eng 2021:4016346 PubMed DOI PMC

Notte SM, Marshall TS, Lee M et al (2012) Content validity and test-retest reliability of Patient Perception of Intensity of Urgency Scale (PPIUS) for overactive bladder. BMC Urol 12:26 PubMed DOI PMC

Meadows KA (2011) Patient-reported outcome measures: an overview. Br J Community Nurs 16(3):146–151 PubMed DOI

Agarwal A, Eryuzlu LN, Cartwright R et al (2014) What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. Eur Urol 65:1211–1217 PubMed DOI PMC

Ghavidel-Sardsahra A, Ghojazadeh M, Rahnama’I MS et al (2022) Efficacy of percutaneous and transcutaneous posterior tibial nerve stimulation on idiopathic overactive bladder and interstitial cystitis/painful bladder syndrome: a systematic review and meta-analysis. Neurourol Urodyn 41:539–551 PubMed DOI

Andersen K, Kobberø H, Pedersen TB, Poulsen MH (2021) Percutaneous tibial nerve stimulation for idiopathic and neurogenic overactive bladder dysfunction: a four-year follow-up single-centre experience. Scand J Urol 55(2):169–176 PubMed DOI

Finazzi Agrò E, Campagna A, Sciobica F et al (2005) Posterior tibial nerve stimulation: is the once-a-week protocol the best option? Minerva Urol Nefrol 57:119–123 PubMed

Yoong W, Ridout AE, Damodaram M, Dadswell R (2010) Neuromodulative treatment with percutaneous tibial nerve stimulation for intractable detrusor instability: outcomes following a shortened 6-week protocol. BJU Int 106:1673–1676 PubMed DOI

Jung CE, Menefee SA, Diwadkar GB (2020) 8 versus 12 weeks of percutaneous tibial nerve stimulation and response predictors for overactive bladder. Int Urogynecol J 31:905–914 PubMed DOI

Krhut J, Tintěra J, Rejchrt M et al (2023) Brain response induced by peroneal electrical transcutaneous neuromodulation invented for overactive bladder treatment, as detected by functional magnetic resonance imaging. Neuromodulation. https://doi.org/10.1016/j.neurom.2022.11.016 PubMed DOI

Blok BF, Groen J, Bosch JL, Veltman DJ, Lammertsma AA (2006) Different brain effects during chronic and acute sacral neuromodulation in urge incontinent patients with implanted neurostimulators. BJU Int 98:1238–1243 PubMed DOI

Bianchi D, Iacovelli V, Parisi I et al (2021) Real-life data on long-term follow-up of patients successfully treated with percutaneous tibial nerve stimulation. Minerva Urol Nephrol 73:260–264 PubMed DOI